SGS742 in Patients With Mild to Moderate Alzheimer's Disease (AD) - Full Text View

Purpose

The purpose of this trial is to determine the effect of a new drug, SGS742, on memory and cognition in patients with mild to moderate Alzheimer's disease.

Condition	Intervention	Phase
Alzheimer's Disease	Drug: SGS742	Phase II

Genetics Home Reference related topics:

Alzheimer disease

MedlinePlus related topics:

Alzheimer's Disease Memory

ChemIDplus related topics:

(3-aminopropyl)(n-butyl)phosphinic acid

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Placebo Control, Safety/Efficacy Study

Official Title:	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase II Study of the Efficacy and Safety of SGS742 in Subjects With Mild to Moderate Alzheimer's Disease

Further study details as provided by National Institute on Aging (NIA):

Estimated Enrollment:	280
Study Start Date:	April 2004
Estimated Study Completion Date:	December 2004

Detailed Description:

SGS742 is a GABA(B) receptor antagonist. It is an orally active drug and possesses neurochemical and psychopharmacologic features that suggest it could improve memory and cognition in humans. The primary objective of the SGS742 clinical trial will be to determine the effect of SGS742 on memory and cognition in individuals diagnosed with mild to moderate Alzheimer's disease. The duration of the study is 3 months with 5 clinic visits.

Eligibility

Ages Eligible for Study:	55 Years to 90 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

55 to 90 years of age
Diagnosed with mild to moderate Alzheimer's disease
Willing caregiver
In general good health

Exclusion Criteria:

Call 1-877-MY-MEMORY and ask to be referred to a study center located near you for entry criteria information.

Prohibited Meds:

Alzheimer's medications (Aricept, Exelon, Remydl, Nemenda)

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00093951

Show 59 Study Locations

Sponsors and Collaborators

Saegis Pharmaceuticals

More Information

Saegis Pharmaceuticals, Inc. This link exits the ClinicalTrials.gov site

Publications:

Froestl W, Gallagher M, Jenkins H, Madrid A, Melcher T, Teichman S, Mondadori CG, Pearlman R. SGS742: the first GABA(B) receptor antagonist in clinical trials. Biochem Pharmacol. 2004 Oct 15;68(8):1479-87.

Study ID Numbers:	IA0061
First Received:	October 7, 2004
Last Updated:	September 18, 2007
ClinicalTrials.gov Identifier:	NCT00093951
Health Authority:	United States: Food and Drug Administration

Keywords provided by National Institute on Aging (NIA):

Alzheimer disease

memory

cognition

GABA(B)receptor antagonist

Study placed in the following topic categories:

Delirium, Dementia, Amnestic, Cognitive Disorders

(3-aminopropyl)(n-butyl)phosphinic acid

Mental Disorders

Alzheimer Disease

Central Nervous System Diseases

Neurodegenerative Diseases

Brain Diseases

Dementia

Cognition Disorders

Delirium

Additional relevant MeSH terms:

GABA Antagonists

Neurotransmitter Agents

Molecular Mechanisms of Pharmacological Action

Therapeutic Uses

Physiological Effects of Drugs

Nervous System Diseases

GABA Agents

Tauopathies

Central Nervous System Agents

Protective Agents

Neuroprotective Agents

Pharmacologic Actions

ClinicalTrials.gov processed this record on October 09, 2008

Sponsored by:	Saegis Pharmaceuticals
Information provided by:	National Institute on Aging (NIA)
ClinicalTrials.gov Identifier:	NCT00093951